The second point of the project involves the development of a platform that will serve the consortium for the production of dendritic cells (DCs) compliant with GMP standards

The third point of the project involves the development of a technological platform for the GMP-grade production of regulatory T cells (Treg)

The fourth point of the project involves the establishment of a GMP-compliant technological platform capable of generating pathogen-specific T cells (PSTs)

The fifth point of the project involves defining and validating a fully standardized platform for immune monitoring, with the goal of identifying predictive markers of response and allowing the harmonization of results in multicentric clinical trials